Theriva Biologics (NYSEAMERICAN:TOVX) Issues Quarterly Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) posted its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, FiscalAI reports.

Theriva Biologics Stock Performance

Shares of TOVX traded up $0.00 during midday trading on Tuesday, reaching $0.38. The stock had a trading volume of 2,359,686 shares, compared to its average volume of 19,985,771. The firm has a 50 day simple moving average of $0.24 and a 200-day simple moving average of $0.24. Theriva Biologics has a one year low of $0.16 and a one year high of $1.45. The firm has a market cap of $12.82 million, a PE ratio of -0.01 and a beta of 1.17. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.11.

Analysts Set New Price Targets

Separately, Maxim Group upgraded Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Theriva Biologics has an average rating of “Buy” and a consensus price target of $1.00.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP acquired a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned 0.64% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is currently owned by institutional investors and hedge funds.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.